OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

home / authors / andrew-d-zelenetz-md-phd-memorial-sloan-kettering-cancer-center

Articles

Advertisement

Next Steps in Mantle Cell Lymphoma

Next Steps in Mantle Cell Lymphoma

March 2nd 2021

Read More


MRD Assessment in Mantle Cell Lymphoma

MRD Assessment in Mantle Cell Lymphoma

March 2nd 2021

Read More


Novel Therapies in the Pipeline in Mantle Cell Lymphoma

Novel Therapies in the Pipeline in Mantle Cell Lymphoma

March 2nd 2021

Read More


MCL: Emerging BTKi-Combination Approaches

MCL: Emerging BTKi-Combination Approaches

February 23rd 2021

Read More


Emerging BTK Inhibitors in Mantle Cell Lymphoma

Emerging BTK Inhibitors in Mantle Cell Lymphoma

February 23rd 2021

Read More


CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

February 16th 2021

Read More

Advertisement

Venetoclax in Mantle Cell Lymphoma

Venetoclax in Mantle Cell Lymphoma

February 16th 2021

Read More


BTK Inhibitors for Relapsed MCL: Important Considerations

BTK Inhibitors for Relapsed MCL: Important Considerations

February 9th 2021

Read More


Selecting a BTKi for Relapsed MCL Treatment

Selecting a BTKi for Relapsed MCL Treatment

February 9th 2021

Read More


Acalabrutinib and Zanubrutinib for Relapsed MCL

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

Read More


BTK Inhibitors for Relapsed Mantle Cell Lymphoma

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

Read More


Lenalidomide and Bortezomib for Mantle Cell Lymphoma

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Read More

Advertisement

Go-To Treatment Regimens in Mantle Cell Lymphoma

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021

Read More


Treatment Approaches in Mantle Cell Lymphoma

Treatment Approaches in Mantle Cell Lymphoma

January 19th 2021

Read More


Accurately Diagnosing Mantle Cell Lymphoma

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Read More

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact